Kalaris Therapeutics (NASDAQ:KLRS) Stock Rating Lowered by Wall Street Zen

Kalaris Therapeutics (NASDAQ:KLRS) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Saturday.

Several other analysts also recently issued reports on KLRS. Citizens Jmp started coverage on Kalaris Therapeutics in a research note on Monday, November 3rd. They set a “market outperform” rating and a $20.00 target price on the stock. Citigroup reiterated an “outperform” rating on shares of Kalaris Therapeutics in a research report on Thursday, December 18th. Chardan Capital initiated coverage on shares of Kalaris Therapeutics in a research report on Tuesday, December 23rd. They set a “buy” rating and a $19.00 target price for the company. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Kalaris Therapeutics in a report on Monday, December 29th. One research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Kalaris Therapeutics has an average rating of “Moderate Buy” and an average price target of $14.00.

Kalaris Therapeutics Price Performance

Shares of KLRS stock opened at $8.88 on Friday. Kalaris Therapeutics has a one year low of $2.14 and a one year high of $12.90. The company’s fifty day moving average price is $8.42 and its 200-day moving average price is $5.69. The company has a market capitalization of $166.07 million, a price-to-earnings ratio of -2.36 and a beta of -0.09.

Kalaris Therapeutics (NASDAQ:KLRS) last issued its quarterly earnings results on Wednesday, November 12th. The company reported ($0.64) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.02.

Institutional Investors Weigh In On Kalaris Therapeutics

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Woodline Partners LP purchased a new stake in Kalaris Therapeutics in the third quarter worth about $1,394,000. Bridgeway Capital Management LLC bought a new stake in shares of Kalaris Therapeutics in the 3rd quarter valued at about $130,000. Johnson Financial Group Inc. purchased a new stake in shares of Kalaris Therapeutics in the 3rd quarter worth approximately $58,000. XTX Topco Ltd purchased a new stake in shares of Kalaris Therapeutics in the 2nd quarter worth approximately $65,000. Finally, Belpointe Asset Management LLC bought a new position in shares of Kalaris Therapeutics during the third quarter valued at approximately $231,000. Institutional investors own 66.05% of the company’s stock.

About Kalaris Therapeutics

Allovir, Inc, a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company’s lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical development product candidates include ALVR106 for the respiratory syncytial virus, influenza, parainfluenza virus, and human metapneumovirus; ALVR109 to treat SARS-CoV-2 and COVID-19; ALVR107 for treating hepatitis B; and ALVR108.